Tuesday, January 6, 2026, yielded two surprising updates from the Food and Drug Administration (“FDA”) Center for Devices and Radiological Health. While many experts have been forecasting continued tension between med tech innovators and the agency based on enforcement trends in 2025, FDA released two policy updates that, in fact, purport to ease the burdens on developers of certain wearables and clinical decision support (“CDS”) software tools.
Introduction
Let’s say FDA proposed a guidance document that would change the definition of “low cholesterol” for health claims. Now let’s say that when FDA finalized the guidance, instead of addressing that topic, FDA banned Beluga caviar. If you are interested in Beluga caviar, would you think you had adequate opportunity to comment? Would you care if FDA argued that Beluga caviar was high in cholesterol so the two documents were related?
Blog Editors
Recent Updates
- The Proposed HHS Budget for 2027: Key Takeaways
- Contractor to Pay More Than $17 Million in First DOJ False Claims Act Settlement Alleging Illegal DEI
- Listen: DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
- FDA Launches Home Innovation Challenge for Medical Device Technologies
- FDA Meeting Invites Stakeholders to Weigh in on Dietary Supplement Ingredients